Form 4: Climb Bio CEO Aoife Brennan Reports RSU Conversion and Tax-Related Stock Sale
Insider Transaction Report
Climb Bio, Inc.'s President and CEO, Aoife Brennan, reported the conversion of 68,750 Restricted Stock Units into common stock and a subsequent sale of 20,618 shares to cover tax withholding obligations.
Summary
- Aoife Brennan, President and CEO, and Director of Climb Bio, Inc. (CLYM), reported transactions involving company stock.
- On June 27, 2025, 68,750 Restricted Stock Units (RSUs) converted into an equal number of common shares.
- On June 30, 2025, 20,618 shares of common stock were sold at a weighted average price of $1.22 per share.
- The sale was executed under a Rule 10b5-1 trading plan, adopted on August 30, 2024, specifically to satisfy tax withholding obligations arising from the RSU vesting and settlement.
- Following these transactions, Aoife Brennan directly owns 48,132 shares of common stock and beneficially owns 206,250 Restricted Stock Units.
- The RSUs were granted on June 27, 2024, and vest over four years, with 25% vesting on each of the first four anniversaries of the grant date, contingent on continued service.
Sentiment
Score: 5
Explanation: The document is a routine Form 4 filing detailing an executive's equity transactions, primarily for tax purposes. It is neutral in sentiment, reporting factual compliance-related events without indicating positive or negative operational or financial performance.
Positives
- The vesting of Restricted Stock Units indicates continued service and commitment of the President and CEO to Climb Bio, Inc.
- The sale of shares was for a specific, routine purpose (tax withholding), not a discretionary sale, which is a common practice for executives.
Negatives
- The sale of 20,618 shares by a key executive, even for tax purposes, reduces their direct ownership stake in the company.
Future Outlook
The remaining 206,250 Restricted Stock Units held by Aoife Brennan are scheduled to vest over the next four years, with 25% vesting annually on the anniversary of the June 27, 2024 grant date, contingent on her continued service to the company.
Management Comments
- The sale reported was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024, to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
Industry Context
This Form 4 filing represents a routine executive compensation event, common across publicly traded companies where executives receive equity as part of their compensation and subsequently sell a portion to cover tax liabilities upon vesting. It does not provide broader insights into industry trends or competitive landscape.
Comparison to Industry Standards
- Not applicable. This Form 4 details a routine insider transaction for tax purposes, which is a standard practice for executives across various industries and does not lend itself to direct comparison with specific company or project performance benchmarks.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Aoife Brennan granted a Power of Attorney to Chandra Adams and Cindy Driscoll of Climb Bio, Inc. to prepare and file SEC Forms 3, 4, and 5 on her behalf, ensuring compliance with Section 16(a) of the Securities Exchange Act of 1934. | 2025-06-26 | Streamlines the process for executive SEC filings, ensuring timely and accurate compliance with reporting requirements. |
Related Party Transactions
- The RSU grant and subsequent vesting and sale of shares for tax purposes are transactions between the company and its President and CEO, which are considered related-party dealings in the context of executive compensation.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO, even for tax purposes, slightly reduces her direct ownership, but the overall impact on shareholder value from this routine transaction is minimal. The continued RSU holdings align executive incentives with shareholder interests.
- Employees: No direct impact on employees mentioned.
- Customers: No direct impact on customers mentioned.
- Suppliers: No direct impact on suppliers mentioned.
- Creditors: No direct impact on creditors mentioned.
Next Steps
- Continued vesting of the remaining 206,250 Restricted Stock Units over the next four years, with 25% vesting annually on the anniversary of the June 27, 2024 grant date.
- Potential future sales of shares by Aoife Brennan to cover tax obligations upon subsequent RSU vesting events.
Key Dates
| Date | Description |
|---|---|
| 2024-06-27 | Grant Date of Restricted Stock Units (RSUs) to Aoife Brennan. |
| 2024-08-30 | Date the Rule 10b5-1 trading plan was adopted by Aoife Brennan. |
| 2025-06-26 | Date of Power of Attorney granting authority to file SEC forms. |
| 2025-06-27 | Date of earliest transaction; conversion of 68,750 Restricted Stock Units into common stock. |
| 2025-06-30 | Date of sale of 20,618 shares of common stock. |
| 2025-07-01 | Signature date of the Form 4 filing. |
Keywords
Climb Bio Inc., CLYM, Aoife Brennan, Form 4, SEC filing, Insider Trading, Restricted Stock Units, RSU, Stock Sale, 10b5-1 Plan, Executive Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.